Acadia Pharmaceuticals
ACAD
272 hedge funds and large institutions have $3.76B invested in Acadia Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 108 increasing their positions, 84 reducing their positions, and 80 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 84
2.21% less ownership
Funds ownership: 93.06% → 90.84% (-2.2%)
12% less funds holding
Funds holding: 308 → 272 (-36)
44% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 80
52% less capital invested
Capital invested by funds: $7.91B → $3.76B (-$4.15B)
57% less call options, than puts
Call options by funds: $43.4M | Put options by funds: $102M
67% less funds holding in top 10
Funds holding in top 10: 9 → 3 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$62.1M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$51.4M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$44M |
| 4 |
HM
HealthCor Management
New York
|
+$39.6M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$28.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$101M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$49.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$46M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$45.4M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$42.3M |
ACAD Hedge Fund Activity: Q1 2021 in Review
272 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2021, worth a combined $3.76B — down 52% from $7.91B a quarter earlier.
Sellers outnumbered buyers: 80 funds closed out of ACAD and 45 opened new positions — a net loss of 35 holders — while 84 trimmed existing stakes and 108 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $62.1M. The largest seller was Fidelity Investments, cutting an estimated $101M.
- 272 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2021, down from 308 in Q4 2020.
- Funds reported $3.76B of Acadia Pharmaceuticals stock for Q1 2021, down 52% quarter-over-quarter.
- 45 funds opened new Acadia Pharmaceuticals positions in Q1 2021 and 80 closed out, a net change of -35 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2021 was Perceptive Advisors, an estimated $62.1M added.
- The largest Acadia Pharmaceuticals seller in Q1 2021 was Fidelity Investments, an estimated $101M sold.
Based on aggregated 13F filings for Q1 2021.